# Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

> **NCT03912389** · PHASE3 · UNKNOWN · sponsor: **Biocad** · enrollment: 292 (estimated)

## Conditions studied

- Non-Squamous Non-Small Cell Neoplasm of Lung

## Interventions

- **BIOLOGICAL:** BCD-100
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin (or carboplatin)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03912389
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 292 (ESTIMATED)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912389, "Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT03912389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*